Aravax’s peanut allergy drug shows benefit in paediatric patients
Aravax’s Phase II peanut allergy trial met its primary endpoint, with younger paediatric patients able to better tolerate peanuts after …
Aravax’s Phase II peanut allergy trial met its primary endpoint, with younger paediatric patients able to better tolerate peanuts after …
At the 2026 American Heart Association (AHA) Scientific Sessions, research was presented that demonstrated encouraging results for the use of …
Novo Nordisk presented the study design and baseline patient characteristics of the ongoing Phase III ARTEMIS trial, evaluating ziltivekimab for …
At this year's American Heart Association (AHA) Scientific Sessions, positive Phase Ib results from a trial evaluating CRISPR Therapeutics' CTX310, …
At this year’s American Heart Association (AHA) conference, hosted in Chicago, Bayer presented a poster presentation featuring a sub-analysis of …
At this year's American Heart Association (AHA) Scientific Sessions, new findings evaluating the impact of concomitant glucagon-like peptide-1 receptor agonist …
At this year's American Heart Association (AHA) Scientific Sessions, primary results from the Phase III Lp(a) HORIZON trial evaluating Novartis' …
At this year's American Heart Association (AHA) scientific sessions, Phase IIb results from the TYDAL-TIMI 78 trial (NCT07028749) evaluating Marea …
Novartis’ marketed therapy, Rhapsido (remibrutinib), has been shown to offer rapid and durable impacts on various subtypes of chronic induced …
Vivani Medical has reported positive topline findings from its Phase I SLIM-1 trial evaluating NPM-139, a subdermal semaglutide implant for …
Vasa Therapeutics has reported positive topline findings demonstrating clinical proof of concept for its lead therapy, VS-041, in a Phase …
Beeline Medicines has unveiled detailed data behind its Bristol Myers Squibb (BMS)- licenced drug afimetoran, which showed it provided statistically …
For a small biotech looking to make the jump into running its first clinical trial, the right CRO can be …
Amgen’s experimental drug, dazodalipeb, has demonstrated its potential as an effective first-in-class option for the treatment of Sjögren's disease, as …
Actinium Pharmaceuticals has begun patient enrolment in its Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89 (RADIANZ) trial, an imaging …